DaVita [DVA] vs Amedisys [AMED] Detailed Stock Comparison
DaVita
NYSE
Loading...
Amedisys
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: DaVita wins in 12 metrics, Amedisys wins in 7 metrics, with 0 ties. DaVita appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | DaVita | Amedisys | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.92 | 39.30 | DaVita |
| Price-to-Book Ratio | 6.41 | 2.69 | Amedisys |
| Debt-to-Equity Ratio | 825.19 | 35.34 | Amedisys |
| PEG Ratio | 5.51 | -2.78 | Amedisys |
| EV/EBITDA | 8.70 | 13.74 | DaVita |
| Profit Margin (TTM) | 6.35% | 3.56% | DaVita |
| Operating Margin (TTM) | 15.70% | 11.70% | DaVita |
| EBITDA Margin (TTM) | 15.70% | 11.70% | DaVita |
| Return on Equity | 57.94% | 6.67% | DaVita |
| Return on Assets (TTM) | 7.15% | 6.52% | DaVita |
| Free Cash Flow (TTM) | $1.47B | $214.29M | DaVita |
| 1-Year Return | -18.38% | 2.68% | Amedisys |
| Price-to-Sales Ratio (TTM) | 0.71 | 1.38 | DaVita |
| Enterprise Value | $23.38B | $3.48B | DaVita |
| EV/Revenue Ratio | 1.78 | 1.45 | Amedisys |
| Gross Profit Margin (TTM) | 33.08% | 43.96% | Amedisys |
| Revenue per Share (TTM) | $164 | $73 | DaVita |
| Earnings per Share (Diluted) | $10.15 | $2.57 | DaVita |
| Beta (Stock Volatility) | 1.12 | 0.90 | Amedisys |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
DaVita vs Amedisys Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| DaVita | -2.30% | 0.28% | -3.54% | -8.00% | -14.68% | -12.45% |
| Amedisys | 0.00% | 0.05% | 3.57% | 7.76% | 9.12% | 11.10% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| DaVita | -18.38% | 50.46% | 49.28% | 79.28% | 263.63% | 429.73% |
| Amedisys | 2.68% | -14.45% | -58.43% | 149.36% | 328.29% | 215.59% |
News Based Sentiment: DaVita vs Amedisys
DaVita
News based Sentiment: MIXED
October was a mixed month for DaVita, marked by a significant cybersecurity incident that created immediate operational and financial risks. However, positive analyst ratings, inclusion in Warren Buffett's portfolio, and indications of undervaluation suggest potential long-term value, creating a complex investment picture.
Amedisys
News sentiment data is not available for Amedisys at this time.
Performance & Financial Health Analysis: DaVita vs Amedisys
| Metric | DVA | AMED |
|---|---|---|
| Market Information | ||
| Market Cap | $9.39B | $3.32B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 638,480 | 1,027,642 |
| 90 Day Avg. Volume | 791,187 | 618,767 |
| Last Close | $128.14 | $100.99 |
| 52 Week Range | $126.07 - $179.60 | $82.15 - $101.02 |
| % from 52W High | -28.65% | -0.03% |
| All-Time High | $179.60 (Jan 27, 2025) | $325.12 (Jan 25, 2021) |
| % from All-Time High | -28.65% | -68.94% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.06% | 0.05% |
| Quarterly Earnings Growth | -0.11% | -0.13% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.04% |
| Operating Margin (TTM) | 0.16% | 0.12% |
| Return on Equity (TTM) | 0.58% | 0.07% |
| Debt to Equity (MRQ) | 825.19 | 35.34 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-4.98 | $37.48 |
| Cash per Share (MRQ) | $10.34 | $10.26 |
| Operating Cash Flow (TTM) | $1.86B | $239.42M |
| Levered Free Cash Flow (TTM) | $1.10B | $300.69M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: DaVita vs Amedisys
| Metric | DVA | AMED |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.92 | 39.30 |
| Forward P/E | 11.64 | 19.76 |
| PEG Ratio | 5.51 | -2.78 |
| Price to Sales (TTM) | 0.71 | 1.38 |
| Price to Book (MRQ) | 6.41 | 2.69 |
| Market Capitalization | ||
| Market Capitalization | $9.39B | $3.32B |
| Enterprise Value | $23.38B | $3.48B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.78 | 1.45 |
| Enterprise to EBITDA | 8.70 | 13.74 |
| Risk & Other Metrics | ||
| Beta | 1.12 | 0.90 |
| Book Value per Share (MRQ) | $-4.98 | $37.48 |
Financial Statements Comparison: DaVita vs Amedisys
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DVA | AMED |
|---|---|---|
| Revenue/Sales | $3.22B | $621.86M |
| Cost of Goods Sold | $2.24B | $348.47M |
| Gross Profit | $983.87M | $273.39M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $433.33M | $72.74M |
| EBITDA | $597.84M | $97.35M |
| Pre-Tax Income | $286.33M | $48.33M |
| Income Tax | $54.12M | $19.27M |
| Net Income (Profit) | $232.22M | $29.05M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DVA | AMED |
|---|---|---|
| Cash & Equivalents | $438.78M | $337.30M |
| Total Current Assets | $3.64B | $662.20M |
| Total Current Liabilities | $2.91B | $488.36M |
| Long-Term Debt | $11.72B | $386.83M |
| Total Shareholders Equity | $1.66B | $1.27B |
| Retained Earnings | $1.70B | $880.25M |
| Property, Plant & Equipment | $11.65B | $229.50M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DVA | AMED |
|---|---|---|
| Operating Cash Flow | $287.94M | $75.50M |
| Capital Expenditures | $-143.26M | $-696,000 |
| Free Cash Flow | $36.75M | $66.29M |
| Debt Repayment | $-345.97M | N/A |
| Common Stock Repurchase | $-541.85M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | DVA | AMED |
|---|---|---|
| Shares Short | 7.51M | 3.20M |
| Short Ratio | 10.82 | 6.84 |
| Short % of Float | 0.21% | 0.10% |
| Average Daily Volume (10 Day) | 638,480 | 1,027,642 |
| Average Daily Volume (90 Day) | 791,187 | 618,767 |
| Shares Outstanding | 80.54M | 32.78M |
| Float Shares | 35.69M | 32.24M |
| % Held by Insiders | 0.50% | 0.02% |
| % Held by Institutions | 0.52% | 0.96% |
Dividend Analysis & Yield Comparison: DaVita vs Amedisys
| Metric | DVA | AMED |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |